Global Chronic Thromboembolic Pulmonary Hypertension Market Size, Status and Forecast 2019-2025

Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Health Organization (WHO), approximately 0.15% to 0.55% of the patients suffering with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension. Due to non-specific symptoms observed in chronic thromboembolic pulmonary hypertension its diagnosis is complex. However, some of the prominent symptoms of chronic thromboembolic pulmonary hypertension are chest discomfort, breathlessness and fatigue. Chronic thromboembolic pulmonary hypertension market can be segmented on the basis of types of diagnosis such as transthoracic echocardiogram (TTE), ventilation-perfusion (V/Q) scan, pulmonary angiography, heart catheterization, computed tomography (CT) pulmonary angiography and other pulmonary function tests.
According to market experts, the diagnosis cases of chronic thromboembolic pulmonary hypertension in regions such as Western Europe and North America was high due to presence of modern technology and rising public awareness about this disease. Regions with rare cases included Asia-Pacific and other geographic regions due to low public awareness and absence of modern diagnostic technologies. North America was observed to be the largest market due to increasing awareness related with chronic thromboembolic pulmonary hypertension and high R&D investments in novel disease diagnostic and treatment technologies.
In 2018, the global Chronic Thromboembolic Pulmonary Hypertension market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Chronic Thromboembolic Pulmonary Hypertension status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chronic Thromboembolic Pulmonary Hypertension development in United States, Europe and China.

The key players covered in this study
Bayer
Johnson & Johnson
Nippon Shinyaku
GlaxoSmithKline
Sun Pharmaceutical Industries
Scipharm SaRL
Promedica International
Medical Research Network
Gilead Sciences
Daiichi Sankyo

Market segment by Type, the product can be split into
Transthoracic Echocardiogram (TTE)
Ventilation-Perfusion (V/Q) Scan
Pulmonary Angiography
Heart Catheterization
Computed Tomography (CT) Pulmonary Angiography
Others

Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Chronic Thromboembolic Pulmonary Hypertension status, future forecast, growth opportunity, key market and key players.
To present the Chronic Thromboembolic Pulmonary Hypertension development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Chronic Thromboembolic Pulmonary Hypertension are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions